Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (LTE AMETHYST)
- Conditions
- Chronic Cutaneous Lupus ErythematosusSubacute Cutaneous Lupus Erythematosus
- Interventions
- Drug: BIIB059 (litifilimab)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 322
- Registration Number
- NCT06044337
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Inland Rheumatology Clinical Trials, Inc., Upland, California, United States
🇺🇸David Fivenson, MD, Dermatology, PLLC, Ann Arbor, Michigan, United States
A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 30
- Registration Number
- NCT05928585
- Locations
- 🇺🇸
HI-Bio Investigational Site, Hialeah, Florida, United States
A TQTc Study for Omaveloxolone
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT05927649
- Locations
- 🇺🇸
Celerion, Inc., Tempe, Arizona, United States
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT05925049
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
An Open-label DDI Study of Omaveloxolone in Healthy Subjects
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT05909644
- Locations
- 🇺🇸
Celerion, Inc., Tempe, Arizona, United States
A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Drug: RTA 901-Matching Placebo
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 209
- Registration Number
- NCT05895552
- Locations
- 🇺🇸
Centricity Research Phoenix Multispecialty, Mesa, Arizona, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Hope Clinical Research, Inc., Canoga Park, California, United States
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 275
- Registration Number
- NCT05798520
- Locations
- 🇺🇸
Vanderbilt MS Center, Nashville, Tennessee, United States
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT05789758
- Locations
- 🇬🇧
St George's University NHS Foundation Trust, London, Greater London, United Kingdom
🇬🇧The Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 10500
- Registration Number
- NCT05767736
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Biogen
- Registration Number
- NCT05764122